Frequency and diagnostic patterns of lymphomas in liver biopsies with respect to the WHO classification by Loddenkemper, Christoph et al.
ORIGINAL ARTICLE
Frequency and diagnostic patterns of lymphomas
in liver biopsies with respect to the WHO classification
Christoph Loddenkemper & Thomas Longerich &
Michael Hummel & Karen Ernestus &
Ioannis Anagnostopoulos & Hans-Peter Dienes &
Peter Schirmacher & Harald Stein
Received: 3 November 2006 /Revised: 18 December 2006 /Accepted: 30 December 2006 / Published online: 13 March 2007
# Springer-Verlag 2007
Abstract The recent World Health Organization (WHO)
classification of hematopoietic and lymphoid tissue tumors
represents the first worldwide consensus classification of
these malignancies. However, the applicability of this
classification to a representative number of hepatic lym-
phomas in liver biopsy specimens has not yet been
investigated. The frequency and infiltration pattern of a
series of 205 liver biopsies with lymphoma manifestations
was analyzed with the aid of immunohistochemical and
molecular pathological analyses. Diffuse large B-cell
lymphoma (DLBCL) was by far the most frequent entity,
comprising 45% of the cases analyzed. Using a previously
published immunohistochemical algorithm, 35% of 80
DLBCL were assigned to a germinal center B-cell-like
(GCB) and 65% to a non-GCB group. Most B-cell
lymphoma entities involving the liver revealed a character-
istic infiltration pattern. Diagnostically challenging entities
were T-cell-rich B-cell lymphomas, anaplastic large cell
lymphomas and peripheral T-cell lymphomas, which
frequently required additional molecular clonality assess-
ment. Overall, the percentage of T-cell lymphomas in the
liver (12%) was higher as compared to other extranodal
sites except for the skin and the small intestine. This study
provides relevant data on the distribution of hepatic
lymphomas and demonstrates the applicability of the
WHO classification proposing a diagnostic algorithm for
liver biopsies.
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Introduction
The liver is most commonly involved in non-Hodgkin
lymphomas (NHL) next to lymph nodes, spleen, and bone
marrow. In the vast majority of cases hepatic involvement
reflects secondary dissemination in advanced disease [15, 18]
rather than a primary site according to the definition of
Caccamo and coworkers [5]. Histopathological analysis of
liver biopsy may be required in patients with an established
diagnosis of malignant lymphoma to differentiate lymphoma
manifestation from other causes of hepatic dysfunction or to
clarify elevated transaminases such as toxic damage because
of chemotherapy or other medications. On the other hand, a
biopsy may reveal a previously unknown lymphoma during
the exploration of a solid hepatic mass or after measuring
elevated liver enzyme serology [12]. Occasionally, a
malignant lymphoma can be detectable in the setting of
other liver diseases such as chronic hepatitis B [20, 22],
chronic hepatitis C [2, 3, 7, 21, 25], or primary biliary
cirrhosis (PBC) [24].
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Cologne, GermanyThe goals of the present study were to test the
feasibility of lymphoma subtyping according to the
World Health Organisation (WHO) classification of
tumors of hematopoietic and lymphoid tissues [16]i n
liver biopsy specimens and to describe the frequencies by
which the different entities occur. For this purpose, a
series of 205 liver biopsies with a diagnosis of malignant
lymphoma were analyzed retrospectively with a specific
focus on the histopathology, especially infiltration pat-
terns, which may ultimately allow the use of diagnostic
algorithms for subtyping of lymphomas in liver biopsies.
This is an important addition in relation to previous
studies, which have mainly described the frequency of
liver involvement in autopsy material of patients with
leukemia or lymphoma [8, 13, 26, 28, 29] differentiating
only between low-grade and high-grade NHL [26]o r
having performed a categorization according to the
outdated Kiel classification [29].
Overall, this study represents the largest series on hepatic
lymphomas to date and due to its restriction to bioptic
material reflects the primary diagnostic situation.
Materials and methods
All cases of hepatic lymphoma involvement diagnosed by
liver biopsy during the years 1994–2003 were retrieved
from the archives of the Institute of Pathology, Campus
Benjamin Franklin, Charité-University Medicine Berlin and
the Institute of Pathology, University of Cologne, Germany.
The series comprised a total of 205 cases with 135 cases
from Berlin and 70 cases from Cologne. All cases were
reevaluated and reclassified independently by three pathol-
ogists (C.L., T.L., H.S.) according to the WHO classifica-
tion [16]. For cases in which the diagnosis was not
unanimous, a final consensus diagnosis was reached after
further immunophenotyping, molecular analyses, and final
consultation. In six cases initially considered “suspicious” for
lymphoma, a final diagnosis of lymphoma was made after
reevaluation and additional analyses. Nine liver biopsies with
insufficient material for additional immunohistochemical or
molecular analyses were excluded beforehand, as well as five
cases where T-cell receptor (TCR) polymerase chain reaction
(PCR) had revealed a polyclonal or oligoclonal rearrange-
ment pattern without a reproducible dominant PCR product.
Overall, 32/205 (16%) cases were reclassified, including
eight “low-grade” [5× B-CLL, 2× follicular lymphomas (FL),
1× marginal zone lymphoma (MZL)] and 20 “high-grade”
[19× DLBCL, 1× Burkitt lymphoma (BL)] B-cell NHL that
were assigned to a specific WHO lymphoma category as well
as four cases with a change in the final diagnosis [BL,
classical Hodgkin lymphoma (cHL), T-cell-rich B-cell lym-
phoma (TCRBCL), lymphoplasmacytic lymphoma (LPL) to
DLBCL, anaplastic large cell lymphoma (ALCL), peripheral
T-cell lymphoma (pTCL) and B-CLL, respectively].
The analyses of the infiltration pattern were based on the
assessment of the hepatic architecture. Three main patterns
were distinguished: Infiltrates for which an exclusive or
predominant association to portal tracts was evident were
recorded as portal infiltrates. The second pattern consisted
of lymphoma infiltrates which showed a coherent growth
pattern thus predominantly resulting in the replacement of
the acinar structures. These infiltrates were designated as a
nodular growth pattern. Finally, infiltrates that showed
Table 1 Antibodies used in this study
Antibody Clone Antigen
retrieval
Dilution Source
ALK1 ALK1 Citrate 1:20 Dako
BCL2 124 Citrate 1:25 Dako
BCL6 594 Citrate 1:25 Dako
CD2 AB75 Citrate 1:50 Novocastra
CD3 F7.2.38 Citrate 1:100 Dako
CD4 1F6 Citrate 1:25 Novocastra
CD5 4C7 Citrate 1:25 Novocastra
CD7 CD7-272 EDTA 1:50 Novocastra
CD8 C8/144B Citrate 1:100 Dako
CD10 56C6 Citrate 1:25 Novocastra
CD15 C3D1 Citrate 1:20 Dako
CD20 L26 Citrate 1:50 Dako
CD21 1F8 Protease 1:50 Dako
CD23 1B12 Citrate 1:20 Novocastra
CD27 137B4 EDTA 1:100 Novocastra
CD30 BerH2 Citrate 1:50 Dako
CD43 DF-T1 Citrate 1:50 Dako
CD68 PG-M1 Citrate 1:50 Dako
CD79a JCB117 Citrate 1:100 Dako
CD138 B-B4 Citrate 1:10 Serotec
Cyclin D1 P2D11F11 Citrate 1:50 Novocastra
EBV-LMP CS1-4 Citrate 1:100 Dako
α-heavychain Rabbit
polyclonal
Citrate 1:40 000 Dako
γ-heavy chain Rabbit
polyclonal
Citrate 1:30 000 Dako
δ-heavy chain Rabbit
polyclonal
Citrate 1:2000 Dako
μ-heavy chain Rabbit
polyclonal
Citrate 1:2000 Dako
Ki-67 MIB-1 Citrate 1:2000 Dako
κ-light chain Rabbit
polyclonal
Citrate 1:100 000 Dako
1-light chain HP6054 Citrate 1:16 000 Dako
MUM1/IRF4 MUM1p Citrate 1:20 Generously
provided by Prof.
B. Falini,
Perugia, Italy
Pax-5 24 Citrate 1:10 Transduction
Laboratories
TIA-1 2G9 Citrate 1:500 Coulter
494 Virchows Arch (2007) 450:493–502prominent intrasinusoidal dispersion of the lymphoma cells
were recorded as a sinusoidal growth pattern. Additionally,
the density of the infiltrate was semiquantitatively assessed.
The presence of scattered neoplastic cells in a background
rich in reactive bystander cells (e.g., nonneoplastic T-cells
and/or macrophages in T-cell rich B-cell lymphoma) was
defined as a loose infiltration pattern, whereas the appear-
ance of coherently appearing neoplastic B- or T-cells was
referred to as a dense infiltrate.
According to clinical information available, in 76/205
(37%) of the cases the diagnosis of a lymphoma had been
previously established from extrahepatic biopsies or pe-
ripheral blood indicating secondary involvement of the
liver. In four of these cases with known low-grade
lymphoma (2× B-CLL, 2× FL) liver biopsy revealed
transformation to a high-grade lymphoma (DLBCL). In
Fig. 1 Nodular pattern: DLBCL of GCB group positive for CD10
(a) and BCL6 (b) and negative for IRF4/MUM1 (few scattered plasma
cells serve as positive intrinsic control; c). CD5 positive DLBCL of
ABC type negative for CD10 (positive bile canaliculi serve as intrinsic
control; d), positive for CD5 (e)a n dI R F 4 / M U M 1( f). TCRBCL with
less than 10% large CD20 positive neoplastic B-cells (g)a s s o c i a t e dw i t h
numerous CD3 positive T-cells (h) and CD68 positive histiocytes (i)
Fig. 2 Size fragment analyses (GeneScan) of the amplificates after
TCR-gamma PCR (primer combination JGT1/2). Fluorescence-la-
belled PCR products (blue lines) were separated on capillary
electrophoresis system (Applied Biosystems, Model 310A) in parallel
to a size standard (red line). The dominant PCR product (arrow)
indicating the presence of a clonal T-cell population was reproducibly
detectable in addition to a moderate oligo-/polyclonal T-cell background
Virchows Arch (2007) 450:493–502 495the remaining cases, the biopsy obtained from the liver
represented the site of primary diagnosis. In 26 (13%)
patients, additional biopsies from extrahepatic sites were
available (13 bone marrow biopsies, 10 lymph node
biopsies, and three spleen biopsies). Furthermore, in a few
cases clinical data regarding a potential predisposing
condition for a primary hepatic lymphoma was available:
chronic hepatitis C was reported in four patients (3×
DLBCL, 1× B-CLL), HIV infection was present in three
patients (2× DLBCL, 1× BL), and one marginal zone
lymphoma occurred in a patient after liver transplantation.
The frequency of the various lymphoma entities diag-
nosed in liver biopsy specimen was compared to their
frequency and distribution in other extranodal sites (cases
from the Consultation and Reference Center for Lymph
Node Pathology and Hematopathology, Berlin).
Immunohistochemistry
For immunostaining, 4 μm thick sections were cut,
deparaffinized, and subjected to heat-induced epitope
retrieval before incubation with antibodies. For this
purpose, sections were immersed either in sodium citrate
buffer at pH 6.0 or, alternatively, in ethylenediamintetra-
acetic acid (EDTA) at pH 8.0 and heated in a high-pressure
cooker. After cooking, the slides were rinsed in running
water, washed with Tris-buffered saline, pH 7.4, and
incubated with the respective primary antibodies. All
primary antibodies employed are listed in Table 1. With
the exception of immunoglobulin detection, in which the
streptavidin–biotin peroxidase method was applied [14],
labeling was carried out using the alkaline–phosphatase/
anti-alkaline–phosphatase complex method [6]. Alkaline
phosphatase was developed using Fast Red as the chromo-
gen, whereas peroxidase was visualized with diaminoben-
zidine chromogen as the substrate.
Molecular pathology analyses
Additional molecular pathology analyses were selectively
performed for those cases in which immunoprofiling alone
was not sufficient to establish a definite diagnosis of a
malignant lymphoma.
For this purpose, DNA was extracted after dewaxing
20-μm-thick paraffin sections with QIAEX (Qiagen, Hil-
den, Germany) according to the manufacturer’s recommen-
dations. TCR-gamma rearrangements were analyzed using
four different primer combinations (JGT1/2, JGT3,
BioMed-2 Set A and Set B). The primer combinations
JGT1/2 und JGT3 suitable to amplify the most frequent
Table 2 Frequency, age distribution and pattern of infiltration in the different lymphoma entities presenting in the liver (Berlin/Cologne 1994–2003)
Berlin Cologne Berlin + Cologne,
n (%)
Age
(range)
Age
(mean)
Male/
female
Pattern Density of
infiltrate
Sinusoidal Portal Nodular Dense Loose
Diffuse large B-cell lymphoma
(DLBCL)
a
52 28 80(39) 16–87 64 50/30 6 19 72 75 5
T-cell rich B-cell lymphoma
(TCRBCL)
9 4 13(6) 35–85 59 9/4 0 11 5 0 13
B-cell chronic lymphocytic leukemia
(B-CLL)
13 13 26(13) 44–82 66 16/10 7 25 2 25 1
Classical Hodgkin lymphoma (cHL) 10 13 23(11) 21–91 54 14/9 1 21 10 3 20
Follicular lymphoma (FL) 11 3 14(7) 38–83 62 7/7 0 11 4 14 0
Marginal zone lymphoma (MZL) 6 1 7(3) 49–80 70 6/1 2 7 0 6 1
Leukemic Plasmacytoma (PL) 4 2 6(3) 61–88 70 4/2 4 1 2 5 1
Burkitt lymphoma (BL) 5 – 5(2) 30–70 47 3/2 0 0 5 5 0
Mantle cell lymphoma (MCL) 3 – 3(1) 60–66 63 2/1 1 3 1 3 0
B-lymphoblastic leukaemia (B-ALL) 2 – 2(1) 18–28 22 1/1 2 0 0 2 0
Hairy cell leukaemia (HCL) 1 – 14 2 – 0/1 1 0 0 1 0
Peripheral T-cell lymphoma,
unspecified (pTCL)
13 5 18(9) 38–84 62 14/4 6 6 8 11 7
Anaplastic large cell lymphoma
(ALCL)
b
5 – 5(2) 24–76 58 5/0 3 3 2 2 3
Hepatosplenic T-cell lymphoma
(HSTCL)
1 1 2(1) 38–51 45 2/0 2 0 0 2 0
Total 135 70 205
aIncluding centroblastic (n=69), immunoblastic (n=3) and anaplastic variant (n=8)
bIncluding one anaplastic large cell lymphoma kinase (ALK) protein positive case
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seminested PCR. The BioMed-2 primer sets A and B able
to detect all possible TCR-gamma rearrangements were
performed as single round PCRs. The detailed cycling
conditions (50 rounds of amplification for BioMed-2 set A
and set B; two-time 35 cycles for primer combinations
JGT1/2 and JGT3) for all PCRs have been described in
detail elsewhere [9, 27].
Amplification of rearranged IgH genes was indepen-
dently performed at least twice per case employing three
different framework primer sets (BioMed-2 FR1, FR2, and
FR3) separately in conjunction with a JH primer (JH22).
PCR conditions consisted of 50 cycles of denaturation
(95°C, 15 s), primer annealing (60°C, 40 s), and elongation
(72°C, 45 s), and the reaction mixture contained 1.5 mM
MgCl2, 0.8 mM deoxyribonucleotide triphosphates
(dNTPs), 70 pmol VH primers, 30 pmol JH22 primer, and
2 U of AmpliTaq Gold polymerase (Applied Biosystems,
Weiterstadt, Germany).
Results
Characteristics of hepatic lymphomas
Almost 90% (182/205) of the hepatic lymphomas belonged
to the group of NHL, whereas only 23 of the 205 cases
were cHL. Regarding NHL, 86% (157/182) were of B-cell
and 14% (25/182) of T-cell origin. Overall, diffuse large
B-cell lymphoma (DLBCL) was the most common type
[51% (93/182) of all B-NHL analyzed] with TCRBCL—a
morphologic variant of DLBCL—comprising 14% (13/93)
of all DLBCL. According to the algorithm of Hans et al. [11]
a predominance of DLBCL of non-GCB (germinal center
B-cell-like) type (52/80; 65%) compared to the DLBCL of
GCB type (28/80; 35%) was found (Fig. 1a–d,f). Only 4
out of 80 cases (5%) corresponded to the group of CD5-
positive DLBCL (Fig. 1e).
In all lymphoma subtypes, men were affected more
often, except for FL, which occurred with equal frequencies
Table 3 Infiltration pattern, differential diagnosis and characteristic immunohistochemical markers
Virchows Arch (2007) 450:493–502 497in both sexes. The male predominance was most striking in
lymphomas of T-cell origin, in which ALCL and hepato-
splenic T-cell lymphoma (HSTCL) were encountered
exclusively in men. Additional molecular analyses were
essential to confirm the suspected diagnosis of a lymphoma
in 5 out of 19 T-cell lymphomas (26%) and 3 out of 116
(3%) B-NHLs (Fig. 2).
The relative frequencies of the lymphoma subtypes, the
available patient data and the infiltration patterns are
summarized in Table 2.
Infiltration patterns of the various lymphoma types
Most of the cases showed the predominance of a certain
growth pattern, although some cases exhibited more than
one growth pattern. Almost all DLBCL and BL showed a
nodular infiltration pattern (91%) composed of a dense
infiltrate (94%; Table 3), except for the TCRBCL variant,
which was located predominantly within the portal tracts
(85%) and exhibited the characteristic scattered infiltrate of
fewer than 10% large neoplastic B-cells admixed with
many reactive T-cells and histiocytes (Fig. 1g–i). Lympho-
mas showing a dense portal infiltration pattern were
chronic lymphocytic leukemia/small lymphocytic lympho-
ma (96%; Fig. 3a–c), FL (79%; Fig. 3d–f), MZL (100%;
Fig. 3g–i), and mantle cell lymphoma (100%). In contrast,
in precursor B lymphoblastic leukemia/lymphoblastic lym-
phoma (B-ALL/B-LBL; Fig. 4a–c), HSTCL (Fig. 4d–f),
leukemic plasmacytoma (Fig. 4g–i), and hairy cell leuke-
mia, a sinusoidal infiltration pattern was observed in the
majority of cases. The cHL displayed a predominantly
portal infiltration pattern (Fig. 5a–c). Peripheral T-cell
Fig. 3 Portal pattern: chronic lymphocytic leukemia (B-CLL) with a
predominantly portal infiltrate of small lymphocytes (a) with
expression of CD23 (b) and CD5 (c). FL (d) with expression of
CD10 (e) and BCL2 (f). Marginal zone B-cell lymphoma with portal
involvement (g), expression of memory B-cell marker CD27 (h) and a
lymphoepithelial lesion of a CK7 positive bile duct (i)
498 Virchows Arch (2007) 450:493–502lymphoma and ALCL showed a spectrum of portal,
sinusoidal, nodular, or mixed patterns with a varying
density of infiltration, and thus did not allow for pattern-
based selection of additional analyses (Fig. 5d–f). The
infiltration patterns, differential diagnoses, and discrimina-
tive immunohistochemical markers are summarized in
Table 3.
Comparison of hepatic lymphomas with other extranodal
lymphomas
The percentage of T-cell lymphomas was considerably
higher in the liver (12%, 25/205) when compared to
other extranodal sites (5%, 165/3252) except for the skin
(50%, mainly mycosis fungoides/Sézary syndrome) and
small intestine (34%, mainly enteropathy-type T-cell
lymphomas).
The high proportion of DLBCL in lymphomas of the liver
(45%) was only surpassed by the small intestine (64%), the
brain (83%), and the testis (97%). Of note, TCRBCL was
extremely rare in other extranodal sites (0,3%) with only a
few cases occurring in the bone marrow and spleen.
Interestingly, one case fulfilled the criteria of TCRBCL in
the liver, and an additional lymph node biopsy showed the
picture of a typical DLBCL, whereas in another case, both
liver and spleen biopsy showed the characteristic features of
TCRBCL. The frequencies of other extranodal lymphomas
compared to hepatic lymphomas are summarized in Table 4.
Fig. 4 Sinusoidal pattern: precursor B lymphoblastic lymphoma
(B-LBL) with a sinusoidal infiltrate of small blasts (a)w i t h
cytoplasmic expression of CD79a (b) and nuclear expression of
terminal deoxynucleotidyl transferase (TdT; c). HSTCL with a
sinusoidal infiltrate of monotonous neoplastic cells (d) with expres-
sion of CD3 (e) and the cytotoxic granule associated protein TIA-1 (f).
Peripheral blood involvement (plasma cell leukemia) in a plasmacy-
toma with a sinusoidal infiltrate of plasma cells (g) with expression of
CD138 (h) and IgG (i)
Virchows Arch (2007) 450:493–502 499Fig. 5 Classical Hodgkin lymphoma vs. anaplastic large cell
lymphoma: cHL with portal infiltrates of Hodgkin and Reed-Sternberg
HRS cells (arrows) in a background rich in eosinophils (a). The HRS
cells strongly express CD30 (b) and the EBV encoded latent
membrane protein 1 (LMP1) (c). Anaplastic large cell lymphoma
(ALCL) with portal infiltrates of pleomorphic large cells resembling
HRS cells (arrows)( d) and strong positivity for CD30 (e) and the
cytotoxic molecule perforin (f)
Table 4 Frequency of extranodal lymphoma at different sites (Berlin 1994–2003)
Brain
(n=31)
Testis
(n=61)
Lung
(n=79)
Bone marrow
(n=1996)
Stomach
(n=855)
Small
intestine
(n=71)
Large
intestine
(n=102)
Spleen
(n=128)
Skin
(n=427)
Liver
(n=135)
DLBCL 25 57 22 66 238 30 32 21 78 52
TCRBCL –––7 –––3 – 9
FL 1 – 2 168 16 3 3 20 91 11
B-CLL 1 – 2 656 12 – 41 0 71 3
PL 3 ––473 –––124
MZL ––40 17 577 4 12 18* 12 6
MCL ––3 107 7 7 41 19 6 3
LPL ––3 122 ––21 3 5–
HCL –––112 –––6 – 1
B-ALL – 1 – 78 –––1 – 2
BL – 1 – 4 – 32– 25
cHL ––35 2 –––31 0 1 0
B-NHL total (%) 30/31
(97%)
59/61
(97%)
75/79
(95%)
1862/1996
(93%)
850/855
(99%)
47/71
(66%)
96/102
(94%)
115/128
(90%)
213/427
(50%)
116/135
(86%)
pTCL 1 – 3 93 4 6 6 12 94 13
NK/T – 1 –– – 2 ––2 –
T-ALL – 1 – 29 ––––9 –
ALCL ––18 1 6 ––26 5
Enteropathy-type
TCL
–––– – 10 ––––
HSTCL –––5 –––1 – 1
MF –––– – – – – 83 –
T-NHL total (%) 1/31
(3%)
2/61 (3%) 4/79
(5%)
134/1996
(7%)
5/855
(1%)
24/71
(34%)
6/102
(6%)
13/128
(10%)
214/427
(50%)
19/135
(14%)
*Including nine cases of splenic marginal zone lymphoma (SMZL)
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To the best of our knowledge, this study represents the
largest series focusing on the histopathology of hepatic
lymphoma involvement and the first application of the
WHO classification of tumors of hematopoietic and
lymphoid tissues for this purpose [16]. Our data demon-
strate the feasibility of in vivo lymphoma subtyping in liver
biopsy with the aid of infiltration pattern analysis, the
selection of differentiating immunophenotypic markers and
additional molecular methods.
Many B-cell-derived lymphomas involving the liver
revealed a characteristic infiltration pattern, which facilitated
the use of a restricted panel of immunohistochemical markers
to reach a final diagnosis. This approach is critical in those
liver biopsies in which a lymphoma diagnosis has previously
not been established, as accurate subtyping of lymphomas is
fundamental for the initiation of adequate treatment.
Diffuse large B-cell lymphomas (DLBCL) accounted for
51% ofallB-NHLcases.DLBCLwasrecentlysubdividedinto
different prognostic groups designated GCB, activated B-cell-
like (ABC or non-GCB) and Type 3, according to their gene
expression profiles [1]. The GCB group is described to have a
better survival than the ABC group and the heterogeneous
Type 3 group. Hans et al. [11] have proposed a simple
immunohistochemical algorithm to assign cases to a GCB
and a non-GCB group. In the present study, the frequency of
either group in 80 liver biopsies with DLBCL was
investigated, excluding the T-cell/histiocyte rich variant (n=
13). DLBCL of non-GCB type (65%) were more frequent in
the liver than the GCB type (35%), whereas these two groups
are described in other sites at about equal frequency [23]. As
liver involvement with malignant lymphomas occurs second-
ary in advanced disease [15, 18], this observation may reflect
the biological behavior of ABC-group DLBCLs through the
selection of more aggressive cases by liver biopsy.
Approximately 10% of the de novo DLBCL express
CD5 [4] and may have a poor outcome [31]. They tend to
be associated with extranodal sites, especially bone marrow
and spleen [19]. In the present series of hepatic lymphoma
involvement, the number of CD5 positive DLBCL (4/80 or
5%) was not increased.
The TCRBCL, a variant of DLBCL in which the majority
of cells are nonneoplastic T-cells and histiocytes, are often
misdiagnosed as a reactive inflammatory condition or as a
T-cell lymphoma infiltration of the liver [8, 17]. TCRBCL is
relatively rare in lymph node biopsies [(23/976) or 2% of
the DLBCL in the Berlin Reference Centre for Lymph
Node Pathology from 1994–2003]. However, in the present
study, 13/93 (14%) of the DLBCL in the liver were found to
fulfill the WHO criteria for TCRBCL thus confirming
previous data from Dargent and coworkers in their series of
62 liver specimens [8]. Additionally, one case with TCRBCL
characteristics in the liver showed the typical morphology
of a conventional DLBCL in an additional lymph node
biopsy. This finding indicates that the composition of the
reactive coinfiltrate may be influenced by the tissue-specific
microenvironment. Therefore, the specific environment of a
certain organ may influence the intensity of the T-cell
response and subsequently explain the higher frequency of
the TCRBCL variant of DLBLC presenting in the liver
[10]. Limitations were encountered in the grading of
follicular lymphoma and the subtyping of the cHL, which
is generally not possible with sufficient certainty in needle
biopsies.
In contrast to B-cell lymphomas, T-cell lymphomas
infiltrating the liver generally lack a typical infiltration
pattern, making their diagnosis more challenging. In
particular, ALCL may mimic cHL due to the possible
resemblance of Hodgkin and Reed-Sternberg cells and
expression of CD30. Thus, additional markers against pan-
Tand pan-B cell antigens (including pax-5), CD15, ALK-1,
cytotoxic molecules, e.g., TIA-1, granzyme B, and per-
forin) are required when confronted with this differential
diagnosis (Fig. 5).
Similarly, the distinction between a T-cell lymphoma and
a drug-induced or viral hepatitis (e.g., due to Epstein-Barr
virus) can be very difficult in biopsies containing an
increased number of sinusoidal T-cells. Therefore, additional
clonality analyses by TCR or IgH PCR were necessary in 5
out of 19 (26%) T-cell lymphomas compared to only 3 out of
116 (3%) B-cell lymphomas to establish a diagnosis.
The reason for the relatively high frequency of liver
involvement by T-cell lymphomas is not known. As T-cells
play an important role in the regulation of the hepatic
immune responses, especially in chronic viral and autoim-
mune hepatitis [30], it is tempting to speculate whether this
may influence the relatively high incidence of T-cell
lymphomas in the liver compared to other extranodal sites.
In the present study, 25 of the 205 (12%) cases were found
to represent lymphomas derived from T-cells, whereas
lymphomas of the testis, brain, lung, and stomach were B-
cell lymphomas in nearly all instances (Table 4).
In summary, the present study demonstrates the
feasibility of subtyping lymphoma infiltrates in liver
biopsies according to the WHO classification. The large
number of 205 cases provides reliable information
regarding the relative frequencies of the different lympho-
ma entities encountered in the liver and demonstrates the
usefulness of infiltration pattern analysis for diagnostic
purposes.
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